Top Alliance Biosciences

Top Alliance Biosciences is the North American research and development subsidiary of Shanghai Junshi Biosciences, a leading innovation-driven biopharmaceutical company. Based in California and Maryland, Top Alliance focuses on the discovery and clinical development of novel therapies across oncology, immunology, and metabolic disease areas. The company's most significant achievement is the development of toripalimab (Loqtorzi), the first China-developed anti-PD-1 monoclonal antibody to receive FDA approval. Top Alliance serves as a strategic bridge, advancing Junshi's extensive pipeline through global clinical trials and regulatory pathways in the United States. Their portfolio includes promising candidates such as tifcemalimab, the first-in-class anti-BTLA monoclonal antibody to enter clinical trials.